Inventor · disambiguated record
Ming Lei
Also filed as: LEI MING · LEI MING-FONG
26 granted patents·32 pending applications·189 citations·filing 2010–2025
96Inventor score
Files withBRISTOL MYERS SQUIBB CO15NOVARTIS AG11NOVAROCK BIOTHERAPEUTICS LTD10UNIVERSAL SEQUENCING TECH CORPORATION4BEIGENE SWITZERLAND GMBH3
Top patents by PatentIndex Score
58 records- 0197US9605080B2Antibodies against CD73BRISTOL MYERS SQUIBB CO·Filed 2016·Granted Mar 28, 2017·31 cites·30 claims
- 0296US10525083B2Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domainNOVARTIS AG·Filed 2017·Granted Jan 7, 2020·15 cites·33 claims
- 0396US10253086B2CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cellNOVARTIS AG·Filed 2016·Granted Apr 9, 2019·37 cites·35 claims
- 0496US10100129B2Antibodies against CD73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Oct 16, 2018·24 cites·35 claims
- 0594US11149076B2CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cellNOVARTIS AG·Filed 2019·Granted Oct 19, 2021·9 cites·32 claims
- 0694US11026976B2Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domainNOVARTIS AG·Filed 2019·Granted Jun 8, 2021·6 cites·23 claims
- 0793US11872249B2Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domainNOVARTIS AG·Filed 2021·Granted Jan 16, 2024·2 cites·38 claims
- 0893US11213586B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)BRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jan 4, 2022·5 cites·14 claims
- 0993US9771562B2Method for culture of human and mouse prostate organoids and uses thereofUNIV COLUMBIA·Filed 2015·Granted Sep 26, 2017·17 cites·14 claims
- 1092US11407828B2Anti-CLauDiN 18 antibodies and methods of use thereofNOVAROCK BIOTHERAPEUTICS LTD·Filed 2020·Granted Aug 9, 2022·3 cites·5 claims
- 1191US10653791B2Antibodies comprising modified heavy constant regionsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted May 19, 2020·10 cites·6 claims
- 1290US10167343B2Antibodies against CD73BRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jan 1, 2019·3 cites·34 claims
- 1389US12344657B2CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cellNOVARTIS AG·Filed 2021·Granted Jul 1, 2025·1 cites·27 claims
- 1488US9290573B2Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodiesCONG FENG·Filed 2011·Granted Mar 22, 2016·16 cites·9 claims
- 1587US8883735B2Low density lipoprotein-related protein 6 (LRP6)-half life extender constructsNOVARTIS AG·Filed 2012·Granted Nov 11, 2014·8 cites·34 claims
- 1680US2023051701A1Antibodies against cd73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 1780US2023374105A1Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)-expressing cellNOVARTIS AG·Filed 2023·Application pending·0 cites
- 1879USRE49847ENucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domainNOVARTIS AG·Filed 2022·Granted Feb 27, 2024·0 cites·35 claims
- 1977US9173960B2Methods of treating cancer with low density lipoprotein-related protein 6 (LRP6)—half life extender constructsNOVARTIS AG·Filed 2014·Granted Nov 3, 2015·2 cites·30 claims
- 2074US2024141059A1Antibodies comprising modified heavy constant regionsBRISTOL MAYERS SQUIBB COMPANY·Filed 2023·Application pending·0 cites
- 2173US12365727B2Anti-interleukin-23 P19 antibodies and methods of use thereofNOVAROCK BIOTHERAPEUTICS LTD·Filed 2022·Granted Jul 22, 2025·0 cites·17 claims
- 2272US11352440B2Antibodies against CD73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 7, 2022·0 cites·18 claims
- 2372US2023272063A1Anti-claudin 18 antibodies and methods of use thereofNOVAROCK BIOTHERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 2471US2022175921A1Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 2571US2023067757A1Anti-claudin 18 antibodies and methods of use thereofNOVAROCK BIOTHERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 2667US2024301051A1Anti-cldn6 antibodies and methods of useBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 2766US11396541B2Anti-interleukin-23 P19 antibodies and methods of use thereofNOVAROCK BIOTHERAPEUTICS LTD·Filed 2020·Granted Jul 26, 2022·0 cites·13 claims
- 2866US2024301061A1Anti-cldn6 and anti-cd3 multispecific antibodies and methods of useBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 2966US2024301062A1Anti-cd3 multispecific antibodies and methods of useBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 3064US2019055320A1Antibodies against cd73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
- 3163US2025340645A1Methods of treating tumorBRISTOL MYERS SQUIBB CO·Filed 2025·Application pending·0 cites
- 3261US11118171B2Recombinant corynebacterium glutamicum for producing lysine by biofilm continuous fermentation and construction method thereofNANJING UNIVERSITY OF TECHNOLOGY·Filed 2020·Granted Sep 14, 2021·0 cites·17 claims
- 3361US2023220453A1Methods and Kits for Tracking Nucleic Acid Target Origin for Nucleic Acid SequencingUNIVERSAL SEQUENCING TECH CORPORATION·Filed 2023·Application pending·0 cites
- 3460US2024383978A1Bispecific binding proteins that bind cd137 and a tumor associated antigenNOVAROCK BIOTHERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 3560US2020268901A1Antibodies comprising modified heavy constant regionsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 3659US11098331B2Method for producing lysine by utilizing adsorption and immobilized fermentation of recombinant corynebacterium glutamicumNANJING UNIVERSITY OF TECHNOLOGY·Filed 2020·Granted Aug 24, 2021·0 cites·8 claims
- 3759US2025145627A1METTL3 Inhibitor and Composition, and Application of Same in MedicineXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 3859US2025002599A1Bispecific and trispecific binding proteins to pd-l1, cd137, and/or tgf-beta and uses thereofNOVAROCK BIOTHERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 3958USRE47860EMethods of treating cancer with low density lipoprotein-related protein 6 (LRP6)—half life extender constructsNOVARTIS AG·Filed 2017·Granted Feb 18, 2020·0 cites·52 claims
- 4058US2023357344A1Interleukin 15 Constructs and Methods of UseBEIGENE LTD·Filed 2021·Application pending·0 cites
- 4156US2025277026A1Antibodies against claudin-6 and uses thereofNOVAROCK BIOTHERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 4255US2020299400A1Antibodies comprising modified heavy constant regionsBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
- 4354US11703469B2Rapid evaluation method for quality of lignin-pyrolyzed bio-oil based on radical detection and application thereofUNIV SOUTHEAST·Filed 2021·Granted Jul 18, 2023·0 cites·9 claims
- 4454US2024124470A1Five-membered ring derivative and medical use thereofSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 4554US2023331867A1Nectin-4 antibodies and uses thereofNOVAROCK BIOTHERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 4654US2023270823A1Long-acting il-15 and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2021·Application pending·0 cites
- 4754US2022041733A1Methods of treating tumorBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 4853US2024067740A1Antibodies to tnfr2 and uses thereofNOVAROCK BIOTHERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 4950US2023031980A1Methods and compositions for treating and diagnosing a sage1-related conditionSHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE·Filed 2020·Application pending·0 cites
- 5047US2022195046A1Methods of treating tumorBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
Showing the top 50 of 58 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Ming Lei files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →